A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination With Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects With Mantle Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

08 Aug 2023 Planned End Date changed from 20 Jun 2027 to 20 Aug 2027.
15 Jun 2023 Updated results (n=38) assessing safety and efficacy of triple combination ABR in patients with TN or R/R MCL presented at the 28th Congress of the European Haematology Association
06 Jun 2023 Results (n=38; as of data cutoff: 15 Jun 22) reporting updated data on safety and efficacy of ABR in patients with TN or R/R MCL presented at the 59th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com